natalizumab
biogen
['#ms ', 'natalizumab']
 late breaking news at #ectrims2022 surprising or not? propensity matched study of #hsct versus #natalizumab in #progressive #ms revealed no difference in efficacy. early treatment best, applies to both 
Professor of Neurology @QMUL & @NHSBartsHealth Here to discuss news & views on #Neurology #MultipleSclerosis #ChariotMS #AttackMS #AssistMS #Politics